Policy
The $1.2 trillion budget package will now move to the Senate, which is expected to hold a vote next week.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former US Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Polarean Imaging plc, the medical-imaging technology company, with a proprietary magnetic resonance imaging (MRI) drug-device combination, announces that the enrolment for its Phase III non-inferiority clinical trials (the “Clinical Trials”) is now complete for both the lung transplant pathway and the lung resection pathway.
The approval marks the first approved treatment in the United States for this condition.
The legal challenges of diversity in the workplace is an issue that every human resources professional needs to take control of to ensure optimal inclusion.
Houston, TX Fannin Innovation Studio announces its receipt of a $2,000,000 Phase II Small Business Innovation Research grant from the National Institute of Health Eunice Kennedy Shriver National Institute of Child Health & Human Development for development of its ChorioAnchor device, in partnership with Texas Children’s Hospital, Baylor College of Medicine, and Texas A&M University
HHS stated that Gilead had “willfully and deliberately induced infringement of the HHS patents.” As a result, “Gilead has profited from research funded by hundreds of millions of taxpayer dollars and reaped billions from PrEP,” through the sale of Truvada and Descovy.
The division previously had three clinical divisions and one nonclinical division. Under the restructuring, it will six divisions, three for oncology.
Artios Pharma Limited, The University of Texas MD Anderson Cancer Center and ShangPharma Innovation announce the in-licensing by Artios of a small-molecule ATR inhibitor programme, developed jointly by MD Anderson and ShangPharma.
Reaffirms Biocon’s Capability to Manufacture Biosimilars for Patients in U.S.
Daiichi Sankyo is taking Seattle Genetics to court over the technology the two companies used to develop antibody-drug conjugates during a partnership that spanned seven years.
A*STAR’s Institute of Bioengineering and Nanotechnology has teamed up with the Singapore Institute of Advanced Medicine Holdings Pte Ltd to explore how to better tackle nasopharyngeal carcinoma, a type of head and neck cancer, through targeted proton therapy.